These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 15319032)

  • 21. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
    Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
    Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
    Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
    Mitrpant C; Fletcher S; Iversen PL; Wilton SD
    J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice.
    Sirsi SR; Schray RC; Guan X; Lykens NM; Williams JH; Erney ML; Lutz GJ
    Hum Gene Ther; 2008 Aug; 19(8):795-806. PubMed ID: 18647087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?
    Yokota T; Duddy W; Echigoya Y; Kolski H
    Expert Opin Biol Ther; 2012 Sep; 12(9):1141-52. PubMed ID: 22650324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renadirsen, a Novel 2'OMeRNA/ENA
    Ito K; Takakusa H; Kakuta M; Kanda A; Takagi N; Nagase H; Watanabe N; Asano D; Goda R; Masuda T; Nakamura A; Onishi Y; Onoda T; Koizumi M; Takeshima Y; Matsuo M; Takaishi K
    Curr Issues Mol Biol; 2021 Sep; 43(3):1267-1281. PubMed ID: 34698059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisense oligonucleotide induced dystrophin exon 45 skipping at a low half-maximal effective concentration in a cell-free splicing system.
    Malueka RG; Yagi M; Awano H; Lee T; Dwianingsih EK; Nishida A; Takeshima Y; Matsuo M
    Nucleic Acid Ther; 2011 Oct; 21(5):347-53. PubMed ID: 21967521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
    van Deutekom JC; Bremmer-Bout M; Janson AA; Ginjaar IB; Baas F; den Dunnen JT; van Ommen GJ
    Hum Mol Genet; 2001 Jul; 10(15):1547-54. PubMed ID: 11468272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
    van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
    Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.
    Aartsma-Rus A; Janson AA; Kaman WE; Bremmer-Bout M; van Ommen GJ; den Dunnen JT; van Deutekom JC
    Am J Hum Genet; 2004 Jan; 74(1):83-92. PubMed ID: 14681829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Terminal antisense oligonucleotide modifications can enhance induced exon skipping.
    Gebski BL; Errington SJ; Johnsen RD; Fletcher S; Wilton SD
    Neuromuscul Disord; 2005 Oct; 15(9-10):622-9. PubMed ID: 16084084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice.
    Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H
    PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
    Errington SJ; Mann CJ; Fletcher S; Wilton SD
    J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of 2'-O-Me RNA/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA.
    Takagi M; Yagi M; Ishibashi K; Takeshima Y; Surono A; Matsuo M; Koizumi M
    Nucleic Acids Symp Ser (Oxf); 2004; (48):297-8. PubMed ID: 17150596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
    He M; Yokota T
    Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.